FDG PET in the management of lymphoma: a clinical perspective

This publication has 17 references indexed in Scilit:

• 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial.
  2001
• Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([¹⁸F]FDG) After First-Line Chemotherapy in Non-Hodgkin’s Lymphoma: Is [¹⁸F]FDG-PET a Valid Alternative to Conventional Diagnostic Methods?
  Journal of Clinical Oncology, 2001
• 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution
  Annals of Oncology, 2000
• Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?
  European Journal Of Cancer, 2000
• 18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CT
  Leukemia & Lymphoma, 2000
• Positron Emission Tomography (PET) for Staging and Evaluation of Response to Treatment in Patients with Hodgkin's Disease
  Leukemia & Lymphoma, 1999
• Whole-body 18F-FDG PET for the evaluation of patients with Hodgkinʼs disease and non-Hodgkinʼs lymphoma
  Nuclear Medicine Communications, 1999
• Positron Emission Tomography with 18-Fluorodeoxyglucose in the Staging and Follow-up of Lymphoma in the Chest
  Acta Oncologica, 1999
• Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
  Radiology, 1997
• Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.
  Radiology, 1994